The p53 inhibitor Mdm4 is present at high levels in multiple human cancers. Overexpression of Mdm4 in mice drives the spontaneous development of mostly lymphomas and sarcomas. In this study, we explored the ability of Mdm4 to cooperate with lesions in tumour development. The Mdm4 transgene contributed to mammary tumour development in a BALB/cJ background. High levels of Mdm4 enhanced tumour development in a mutant p53R172H heterozygous background, and reduced the need to lose the wild-type p53 allele, as compared with mice heterozygous only for the p53R172H mutation. Additionally, high levels of Mdm4 cooperated with an oncogenic K-ras mutation to drive lung tumourigenesis in vivo. Finally, we examined p53-independent functions of Mdm4 by studying the contribution of Mdm4 to tumour development in the absence of p53. Whereas the overall survival times of p53-null mice with and without the Mdm4 transgene were similar, male mice with both alterations showed significantly shorter survival than p53-null male mice, and showed differences in tumour spectrum, demonstrating a p53-independent function of Mdm4 in tumourigenesis. Furthermore, p53-null mice with the highest level of Mdm4 tended to have multiple tumours. Thus, a detailed analysis of Mdm4 transgenic mice in various genetic backgrounds shows synergy in tumour development in vivo. Mdm4 may thus serve as a therapeutic target in cancers.
Introduction
Mdm2 and Mdm4 are critical inhibitors of the p53 tumour suppressor, and are often overexpressed in human cancers [1] . Loss of either of the genes encoding these proteins in mice leads to embryo-lethal phenotypes that are completely rescued by p53 deletion [2] [3] [4] [5] [6] . Whereas Mdm2 is an E3 ligase that targets p53 for proteasomal degradation, the homologue Mdm4 inhibits p53 activity by binding to the p53 N-terminal transactivation domain [7, 8] . Although Mdm4 itself does not have a E3 ubiquitin ligase function, it modulates p53 stability by interacting with Mdm2 through its RING domain [9] . Disruption of this interaction leads to p53-dependent embryo-lethal phenotypes [10, 11] . Thus, Mdm4 is a genuine p53 negative regulator in development.
Conversely, a variety of human cancers have MDM4 amplification and overexpression, resulting in high levels of MDM4 protein [1, [12] [13] [14] [15] [16] . In most cases, human tumours with high levels of MDM4 do not have alterations in TP53, further emphasizing the mutually exclusive relationship between MDM4 and TP53 alterations [1] . However, some tumours do have high levels of both MDM4 and TP53 mutations, prompting us to examine the cooperativity of the two events in tumour development in mouse models. For example, whereas 14% of invasive breast cancers have amplified MDM4, 3% also have mutations in TP53 (www.Cbioportal .com). The relationship between Mdm4 and mutant p53 is complex. Mdm4 binds the N-terminus of wild-type p53 and probably binds mutant p53, as the latter retains the N-terminus. As Mdm4 binding interferes with Mdm2, and Mdm4 lacks a E3 ubiquitin ligase function, this interaction probably contributes to mutant p53 stability. Increased stability of mutant p53 proteins leads to gain-of-function activities [17] , and these data suggest that increased Mdm4 levels may cooperate with mutant p53 in tumourigenesis. Additional in vivo experiments are needed to determine the effects of increased Mdm4 levels and p53 mutations on tumour development.
In addition, we examined the cooperativity of high levels of Mdm4 with other alterations in tumour development. A large proportion (36%) of lung 502 S Xiong et al adenocarcinoma patients have KRAS mutations. Of these, 3.5% have both KRAS mutations and MDM4 amplification in the TCGA dataset (www.Cbioportal .com). As it is known that p53 loss cooperates with oncogenic K-ras in lung tumour models [18] , we also examined whether Mdm4 overexpression could cooperate with oncogenic K-ras in lung adenocarcinoma tumourigenesis.
Moreover, the fact that some tumours have both high MDM4 levels and TP53 mutations suggests possible p53-independent functions of MDM4. Besides binding to p53 and Mdm2, Mdm4 also interacts with other proteins, such as p21, 14-3-3gamma, ARF, HAUSP, and Nbs1 [19] [20] [21] [22] [23] [24] [25] , suggesting that Mdm4 has p53-independent functions. Specifically, Mdm4 promotes genomic instability and increases cell transformation independently of p53 and Mdm2 by interacting with Nbs1 [25] , further suggesting that Mdm4 has a p53-independent function. This relationship has not been examined in tumour models in vivo.
We have previously generated Mdm4-overexpressing transgenic mice with varying levels of Mdm4, ranging from lowest to highest in Mdm4 Tg1 , Mdm4 Tg6 , and Mdm4 Tg15 . Mdm4 overexpression in mice in a mixed C57BL/6 J and129/SvJ background leads to the development of lymphomas, sarcomas, and a few carcinomas [26] , demonstrating that Mdm4 acts as an oncogene when overexpressed. As the BALB/cJ background is more permissive for the development of mammary tumours [27] [28] [29] , we crossed Mdm4 transgenic mice into a BALB/cJ background to assess the role of Mdm4 in mammary tumours. These mice developed mammary tumours. Mdm4 overexpression in a p53 R172H/+ background decreased survival and increased tumour incidence. Mdm4 overexpression cooperated with oncogenic K-ras in lung adenocarcinoma genesis. Additionally, p53-independent functions of Mdm4 were observed in male mice in a p53-null background. In summary, our results support the idea that Mdm4 is a genuine oncogene, as it cooperates with genetic lesions to drive tumour development.
Materials and methods

Mice and tumour analyses
Mouse experiments were performed in compliance with the MD Anderson Cancer Center's Institutional Animal Care and Use Committee. Mdm4
Tg1 , Mdm4 Tg6 and Mdm4 Tg15 mice [26] were back-crossed with BALB/cJ wild-type mice (Jackson Laboratory, Bar Harbor, ME, USA) for at least six generations. p53 R172H/+ mice in a BALB/cJ background were generated previously [30] . K-ras LA1/+ mice [18] were purchased from Jackson Laboratory, and crossed with Mdm4
Tg6 or Mdm4 Tg15 mice in a mixed C57BL/6 J and 129/SvJ background. Mouse cohorts were monitored daily for tumourigenesis. Moribund mice were killed, and tissues were prepared for pathological analyses.
Immunohistochemistry (IHC)
Mdm4 IHC was performed as described previously, with AB112 antibody [13] . FL-393 (Santa Cruz Biotechnology, Dallas, TX, USA) was used for p53 IHC (1:50 dilution). The Vector DAB Substrate Kit (Vector Laboratories, Burlingame, CA, USA) was used for chromogenic detection.
p53 loss of heterozygosity (LOH) assay
Polymerase chain reaction (PCR) amplification was performed on tumour DNA samples, and the products were sequenced. p53 LOH was determined as previously described [31] .
Western blot analysis and reverse transcription quantitative PCR (RT-qPCR) R172H/+ mice presented as the percentage of each tumour type out of the total number of tumours for each genotype. The total number of tumours examined by pathologists for each genotype is indicated in parentheses above each bar. (C) Overexpression of Mdm4 increased multiple tumour incidence rates in the double-mutant mice. **p < 0.01 and ***p < 0.001.
Statistical analysis
Student's t-tests and Kaplan-Meier survival analyses were performed with Prism 5 software (GraphPad Software, La Jolla, CA, USA). P-values of <0.05 were considered to be statistically significant.
Results
Overexpression of Mdm4 drives mammary tumour development in a BALB/cJ background
Mdm4
Tg6 and Mdm4 Tg15 mice were generated previously in a C57BL/6 J and 129/SvJ mixed background by use of a promoter that expresses high levels of Mdm4 in multiple tissues [26] . To investigate whether overexpression of Mdm4 plays a causative role in mammary tumourigenesis, Mdm4
Tg6 and Mdm4
Tg15
mice were back-crossed with BALB/cJ mice, which are predisposed to spontaneous breast tumour development [27] [28] [29] . All of the mice were monitored for tumourigenesis within the same time frame. Mdm4 Tg6 and
Mdm4
Tg15 mice developed different types of tumours, with median overall survival times of 538 and 489 days, respectively ( Figure 1A ). Mdm4 Tg6 mice developed lymphomas (56%), haemangiosarcomas (26%), and carcinomas (7%). Similarly, Mdm4
Tg15 mice developed lymphomas (34%), sarcomas (25%), and carcinomas (31%) ( Figure 1B and Table 1 ). Moreover, 25% of 
Tg6 and 26% of Mdm4 Tg15 mice had two or more tumours ( Figure 1C ), demonstrating that Mdm4 is a potent oncogene that drives tumour development in vivo. Interestingly, although with low penetrance, both Mdm4
Tg6 (1/20) and Mdm4 Tg15 (2/23) transgenic mice developed mammary adenocarcinoma ( Figure 2A and Table 1 differentiated to focally poorly differentiated with increased mitosis, angiogenesis, and fibrosis. Also, Mdm4 Tg6 and Mdm4 Tg15 mice both developed testicular interstitial cell (Leydig) adenoma, and tumours in Mdm4
Tg15 mice even progressed to Leydig cell carcinoma (one metastasized to lung) ( Figure 2C, D) . Notably, Leydig cell carcinomas are not observed in
Tg15 mice in a C57BL/6 J and 129/SvJ mixed background [26] , indicating that a BALB/cJ background may contribute to Leydig cell tumourigenesis in these mice. Furthermore, all of the mammary adenocarcinomas (n = 3) and Leydig cell tumours (n = 4) from the transgenic mice were stained positively for Mdm4 by IHC ( Figure 2B, E) , indicating that overexpression of Mdm4 contributed to tumourigenesis. Consistent with previous studies [26] , 70% of tumours (7/10) from Mdm4 Tg6 mice and 67% of tumours (6/9) from Mdm4 Tg15 mice showed p53 IHC staining. More than half of the tumours (10/19) had positive staining for both Mdm4 and p53 ( Figure 2F, G) , which was consistent with our previous data [26] . The lymphomas were stained for T-cell-specific (CD3) and B-cell-specific (B220) markers to determine the cell of origin; lymphomas from Mdm4 Tg6 mice were all of B-cell origin (5/5), and those from Mdm4 Tg15 mice were of both B-cell and T-cell origin ( Figure 2H -J and data not shown). To determine whether Mdm4 suppresses p53 activity and propels tumour growth, Mdm4 knockdown experiments were performed in a primary sarcoma tumour cell line from an Mdm4
Tg15 mouse ( Figure 2K ). Mdm4 knockdown significantly increased the transcript levels of p53 downstream target genes ( Figure 2L ), and slowed proliferation ( Figure 2M ). Thus, decreasing Mdm4 levels allowed reactivation of functional p53 in these cells. (Table 2) . RT-qPCR was used to examine the level of expression of Mdm4 in 20 tumour samples from double-mutant mice. All showed significantly higher Mdm4 mRNA levels in double-mutant tumours than in p53 R172H/+ tumours ( Figure 3A) . Consistently, 82% (9/11) Tg15 p53 R172H/+ mice retained the wild-type p53 allele, demonstrating that overexpression of Mdm4 reduced the selective pressure to lose the wild-type p53 allele in these tumours during tumour evolution ( Figure 3C ). Consistently, IHC performed on 20 tumours from Mdm4
Overexpression of
Tg6 p53 R172H/+ and Mdm4 Tg15 p53 R172H/+ mice showed that only tumours with Mdm4 overexpression had stabilized p53, including 10 tumours with p53 LOH (tumours only having mutant p53 protein) and six tumours without p53 LOH (tumours having both mutant and wild-type p53 proteins) ( Figure 3B ). These data indicated that overexpression of Mdm4 stabilizes p53 irrespective of its mutation status in tumours.
Mutant p53 shows gain-of-function activities through multiple downstream regulators and pathways, including activation of the mevalonate pathway [35] , chromatin methyltransferases and acetyltransferases [36] , transforming growth factor-β/p63 [37] , platelet-derived growth factor receptor-β [38] , and Pla2g16 [30] . To investigate whether increased Mdm4 levels could also affect mutant p53 gain of function, Mdm4 was overexpressed in H318-1 osteosarcoma cells ( Figure 3D ), a mouse primary tumour cell line generated from p53 R172H/+ osteosarcomas that had lost the wild-type p53 allele [39] . Analysis of mRNA levels of the reported mutant p53 target genes showed decreased expression of these genes except for Hmgcr and Mll1 ( Figure 3E ). Thus, increased Mdm4 levels stabilized mutant p53 and decreased its gain-of-function potential by masking its transcriptional activation domain. 
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Overexpression of Mdm4 cooperates with oncogenic K-ras in tumourigenesis
p53 loss accelerates lung adenocarcinoma development in K-ras LA1/+ mice [18] . As ∼6% of lung adenocarcinoma patients with K-ras mutations have increased copy numbers of MDM4 (www.Cbioportal.com), we wished to investigate whether Mdm4 overexpression could cooperate with the K-RasG12D mutation in lung tumourigenesis in vivo. We therefore crossed both Mdm4 Tg6 and Mdm4 Tg15 mice with K-ras LA1/+ mice in a C57BL/6 J and 129/SvJ mixed background. Overexpression of Mdm4 significantly accelerated tumourigenesis in both Mdm4 Tg6 K-ras LA1/+ (n = 20) and Mdm4 Tg15 K-ras LA1/+ (n = 14) mice as compared with K-ras LA1/+ littermates ( Figure 4A ). Both double-mutant mice had significantly shorter median survival times, i.e. 267 and 255 days, respectively, than the median survival time of K-ras LA1/+ mice (n = 20), i.e. 341 days. Additionally, Mdm4 IHC staining was positive in 60% of lung adenocarcinomas from the double-mutant mice ( Figure 4B ), suggesting that overexpression of Mdm4 contributes to lung tumourigenesis.
Mdm4 has p53-independent functions in vivo
MDM4 interacts with a variety of proteins in different human cell lines, such as p21, 14-3-3gamma, ASPP, ARF, p300, Smads, and RB [19, [21] [22] [23] [40] [41] [42] , suggesting that it has p53-independent functions. Also, MDM4 promotes genomic instability by associating with Nbs1 to promote cell transformation [25] . In order to investigate whether different levels of Mdm4 overexpression contribute to its p53-independent functions, we chose Mdm4
Tg1 mice with a relatively low expression level and Mdm4
Tg15 mice with a higher expression level to generate the cohorts of Mdm4 respectively. However, when the survival data were segregated in a gender-specific manner, the median survival time of Mdm4
Tg15 p53 −/− (n = 15) male mice was significantly shorter than that of p53 −/− male mice (n = 25) (98 versus 130 days, p = 0.0042), but the median survival time of p53 −/− female mice was similar to that of Mdm4 Tg15 p53 −/− female mice (data not shown), indicating that Mdm4 overexpression accelerated tumourigenesis in a p53-null background through p53-independent functions in these male mice ( Figure 5B ). In mice with or without the Mdm4 Tg1 transgene, p53 loss did not alter the median survival time in either male or female cohorts, suggesting that the p53-independent function of Mdm4 may depend on the expression levels of Mdm4 (data not shown). Another interesting observation is that six different types of sarcoma arose in p53 −/− mice, whereas both Mdm4 Tg1 p53 −/− and Mdm4
Tg15 p53 −/− mice developed a more limited sarcoma type (Table 3) . Whereas 34% of p53 −/− mice (10/29) and 32% of Mdm4 Tg1 p53 −/− mice (6/19) had two or more tumours, 55% of Mdm4 Tg15 p53 −/− mice (6/11) had two or more tumours ( Figure 5C ), implying that overexpression of Mdm4 at a higher level led to a worse tumourigenic phenotype even in the absence of p53. In addition, we also observed Mdm4 overexpression in 57% of Mdm4 Tg15 p53 −/− tumours (4/7), but not in any of the tumours from p53 −/− (eight tumours) or Mdm4
Tg1 p53 −/− (seven tumours) mice ( Figure 5D ). Overexpression of Mdm4 in two primary tumour cell lines from p53 −/− mice ( Figure 5E ) showed increased cell proliferation ( Figure 5F ) suggesting that Mdm4 contributed to cell proliferation independently of p53. Taken together, these data indicate that overexpression of Mdm4 in the absence of p53 contributed to tumour development.
Discussion
High levels of MDM4 were first observed in ∼19% of breast cancer patients [12] . Subsequently, 14% of invasive lobular breast cancers were also found to have MDM4 amplification [43] , and TCGA data demonstrated that MDM4 amplification is a common event in breast cancer [14] . In this study, using two Mdm4 transgenic mouse lines in a BALB/cJ background that is sensitized to breast tumour development, we demonstrated that Mdm4 overexpression directly contributes to mammary tumourigenesis. However, the low incidence of mammary tumours in Mdm4-overexpressing transgenic mice suggests that additional genetic changes are required. The other possibility is that high Mdm4 levels cooperated more readily in lymphomagenesis in Mdm4-overexpressing mice.
Mdm4 overexpression in a p53 R172H/+ background also accelerated tumourigenesis and reduced the selective pressure to lose wild-type p53 in tumours, demonstrating that high Mdm4 levels do indeed contribute to tumourigenesis in the presence of a hotspot p53R172H mutation. Thus, tumours with high levels of both Mdm4 and p53 mutations are likely to retain the wild-type p53 allele, suggesting that it will be beneficial to use Mdm4 inhibitors to treat these cancers. In the above examples, high levels of Mdm4 stabilized mutant p53 in many but not all tumours, but no obvious gain-of-function phenotypes of mutant p53 were observed, suggesting that Mdm4 binding to mutant p53 may hinder its association with other proteins to inhibit gain-of-function activities.
Finally, overexpression of Mdm4 changed the tumour spectrum in p53 −/− mice. Specifically, a higher percentage of Mdm4
Tg15 p53 −/− mice than of p53 −/− mice developed multiple tumours. Mdm4
Tg15 p53 −/− male mice had a significantly shorter median survival time than p53 −/− male mice, demonstrating that Mdm4 overexpression had a p53-independent function. It is interesting to note that overexpression of Mdm4 accelerated tumourigenesis only in male mice. Mdm4 binds numerous other proteins besides p53, such as Smad, Nbs1, and UXT; perhaps one or more of these proteins are present at different levels in males versus females [25, 41, 44] . Additionally, high levels of Mdm4 also contribute to worse tumour phenotypes in Mdm4
Tg6 p53 R172H/+ and Mdm4
Tg15 p53 R172H/+ mice, which could be at least partly due to p53-independent functions of Mdm4. However, the mechanism of these p53-independent functions of Mdm4 in tumourigenesis will need further investigation. As MDM4 overexpression or amplification is a common event in a variety of human cancers, and Mdm4 overexpression reduces the need to lose the wild-type p53 allele, Mdm4 inhibitors may activate p53. Moreover, Mdm4 inhibition induces less toxicity than Mdm2 
